CRANBURY, N.J.--(BUSINESS WIRE)--Michel Sadelain, M.D., Ph.D., will join Physicians’ Education Resource® (PER®), the leading resource for hematology and oncology continuing medical education (CME) as the keynote for the Greenspan Lecture, titled, T Cell Engineering for Cancer Immunotherapy during the upcoming Chemotherapy Foundation Symposium® (CFS®). This year’s CFS® will take place Nov. 9 at 11 a.m. at the New York Marriott Marquis, announced Phil Talamo, president of PER®.
“We are thrilled to have Dr. Sadelain share his expertise during the Greenspan Lecture. His innovations in the arenas of T cell engineering and cancer immunotherapy has made a positive impact on cancer treatment. We look forward to him sharing his expertise with the attendees, who can apply similar strategies to offer optimized care for their patients,” said Talamo.
Dr. Sadelain is the director of the Center for Cell Engineering at the Memorial Sloan Kettering Cancer Center (MSK) in New York City. His research with CAR-T cells, which he pioneered at MSKCC, has made major contributions to cancer treatments. He is also the head of the Gene Transfer and Gene Expression Laboratory at MSK. In addition to his clinical research, he has authored more than 200 scientific papers and book chapters.
CFS® Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is a three-day educational event. The Greenspan Lecture is named after the renowned chemotherapy pioneer, Dr. Ezra Greenspan, whose research and innovation contributed to the development of breast and ovarian cancer treatments in the late 1940’s. The lecture which honors innovation, features a keynote speaker who has contributed to the field of oncology through groundbreaking research and development. Additionally, the event provides a platform for oncologists, hematologists and other medical professionals to gather and exchange ideas and strategies about recent developments in the field of chemotherapy.
For more information about the event and to register, visit www.gotoper.com/go/CFS17TB
Since 1995, PER® has been the leading provider of live, online and print CME activities focusing on oncology and hematology by providing high-quality, evidence-based activities featuring leading experts who focus on the application of practice-changing advances. In 2017, PER® will develop and implement 21 historic annual legacy conferences in the Unites States and Europe, along with many world-renowned online learning formats. PER® is also the publisher of the monthly peer-reviewed American Journal of Hematology/Oncology® and accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based Michael J. Hennessy Associates, Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.